Different toll-like receptor expression patterns in progression toward cancer

Frontiers in Immunology

Volumn 5, Issue DEC, 2014, Pages

  Jouhi, Lauri ^a   Renkonen, Suvi ^a   Atula, Timo ^a   Mäkitie, Antti ^a   Haglund, Caj ^a   Hagström, Jaana ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Carcinoma; Immunohistochemistry; Innate immunity; Pattern recognizing receptors; Pre malignant lesions

Indexed keywords

HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5;

ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CELL MEMBRANE; CELL PROLIFERATION; CYTOKINE PRODUCTION; IMMUNE RESPONSE; INFLAMMATION; NEOPLASM; NOTE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84919481266     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2014.00638     Document Type: Note

References (32)

1. Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb Symp Quant Biol (1989) 54(Pt 1):1-13. doi: 10.1101/SQB.1989.054.01.003
2. Medzhitov R, Janeway CA Jr. Innate immunity: the virtues of a nonclonal system of recognition. Cell (1997) 91(3):295-8. doi:10.1016/S0092-8674(00)80412-2
3. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun (2009) 388(4):621-5. doi:10.1016/j.bbrc.2009.08.062
4. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol (1994) 12:991-1045. doi:10.1146/annurev.immunol.12.1.991
5. Matzinger P. The danger model: a renewed sense of self. Science (2002) 296(5566):301-5. doi:10.1126/science.1071059
6. Kawai T, Akira S. Pathogen recognition with toll-like receptors. Curr Opin Immunol (2005) 17(4):338-44. doi:10.1016/j.coi.2005.02.007
7. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in cancer: a double-edged sword for defense and offense. Arch Pharm Res (2012) 35(8):1297-316. doi:10.1007/s12272-012-0802-7
8. Zur Hausen H. Condylomata acuminata and human genital cancer. Cancer Res (1976) 36(2 Pt 2):794.
9. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 325(16):1127-31. doi:10.1056/NEJM199110173251603
10. Bargen JA. Chronic ulcerative colitis associated with malignant disease. 1928. Dis Colon Rectum (1994) 37(7):727-30. doi:10.1007/BF02054420
11. Beasley RP, Hwang LY, Lin CC, Chien CS. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 2(8256):1129-33. doi:10.1016/S0140-6736(81)90585-7
12. Huang B, Zhao J, Li H, He KL, Chen Y, Chen SH, et al. Toll-like receptors on tumor cells facilitate evasion of immune surveillance. Cancer Res (2005) 65(12):5009-14. doi:10.1158/0008-5472.CAN-05-0784
13. Schmausser B, Andrulis M, Endrich S, Muller-Hermelink HK, Eck M. Toll-like receptors TLR4, TLR5 and TLR9 on gastric carcinoma cells: an implication for interaction with Helicobacter pylori. Int J Med Microbiol (2005) 295(3):179-85. doi:10.1016/j.ijmm.2005.02.009
14. Droemann D, Albrecht D, Gerdes J, Ulmer AJ, Branscheid D, Vollmer E, et al. Human lung cancer cells express functionally active toll-like receptor 9. Respir Res (2005) 6:1. doi:10.1186/1465-9921-6-68
15. Helminen O, Huhta H, Takala H, Lehenkari PP, Saarnio J, Kauppila JH, et al. Increased toll-like receptor 5 expression indicates esophageal columnar dysplasia. Virchows Arch (2014) 464(1):11-8. doi:10.1007/s00428-013-1505-2
16. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al. Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 133(6):1869-81. doi:10.1053/j.gastro.2007.09.008
17. He W, Liu Q, Wang L, Chen W, Li N, Cao X. TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol (2007) 44(11):2850-9. doi:10.1016/j.molimm.2007.01.022
18. Okamoto M, Oshikawa T, Tano T, Ohe G, Furuichi S, Nishikawa H, et al. Involvement of toll-like receptor 4 signaling in interferon-gamma production and antitumor effect by streptococcal agent OK-432. J Natl Cancer Inst (2003) 95(4):316-26. doi:10.1093/jnci/95.4.316
19. Lowe EL, Crother TR, Rabizadeh S, Hu B, Wang H, Chen S, et al. Toll-like receptor 2 signaling protects mice from tumor development in a mouse model of colitis-induced cancer. PLoS One (2010) 5(9):e13027. doi:10.1371/journal.pone.0013027
20. Matijevic T, Marjanovic M, Pavelic J. Functionally active toll-like receptor 3 on human primary and metastatic cancer cells. Scand J Immunol (2009) 70(1):18-24. doi:10.1111/j.1365-3083.2009.02262.x
21. Bauer AK, Dixon D, DeGraff LM, Cho HY, Walker CR, Malkinson AM, et al. Toll-like receptor 4 in butylated hydroxytoluene-induced mouse pulmonary inflammation and tumorigenesis. J Natl Cancer Inst (2005) 97(23):1778-81. doi:10.1093/jnci/dji403
22. Kauppila JH, Mattila AE, Karttunen TJ, Salo T. Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer (2013) 108(3):638-43. doi:10.1038/bjc.2012.589
23. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al. High expression of toll-like receptor 4/myeloid differentiation factor 88 signals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010) 102(5):908-15. doi:10.1038/sj.bjc.6605558
24. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr, et al. Decreased toll-interacting protein and peroxisome proliferator-activated receptor are associated with increased expression of toll-like receptors in colon carcinogenesis. J Clin Pathol (2012) 65(4):302-8. doi:10.1136/jclinpath-2011-200567
25. Pimentel-Nunes P, Goncalves N, Boal-Carvalho I, Afonso L, Lopes P, Roncon-Albuquerque R Jr, et al. Helicobacter pylori induces increased expression of toll-like receptors and decreased toll-interacting protein in gastric mucosa that persists throughout gastric carcinogenesis. Helicobacter (2013) 18(1):22-32. doi:10.1111/hel.12008
26. Hagstrom J, Heikkila A, Siironen P, Louhimo J, Heiskanen I, Maenpaa H, et al. TLR-4 expression and decrease in chronic inflammation: indicators of aggressive follicular thyroid carcinoma. J Clin Pathol (2012) 65(4):333-8. doi:10.1136/jclinpath-2011-200402
27. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med (2007) 13(1):54-61. doi:10.1038/nm1523
28. Shi Y, Zheng W, Rock KL. Cell injury releases endogenous adjuvants that stimulate cytotoxic T cell responses. Proc Natl Acad Sci U S A (2000) 97(26):14590-5. doi:10.1073/pnas.260497597
29. Krysko O, Love Aaes T, Bachert C, Vandenabeele P, Krysko DV. Many faces of DAMPs in cancer therapy. Cell Death Dis (2013) 4:e631. doi:10.1038/cddis.2013.156
30. Castellani P, Balza E, Rubartelli A. Inflammation, DAMPs, tumor development, and progression: a vicious circle orchestrated by redox signaling. Antioxid Redox Signal (2014) 20(7):1086-97. doi:10.1089/ars.2012.5164
31. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I, et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res (2012) 72(13):3290-301. doi:10.1158/0008-5472.CAN-11-3481
32. Kang R, Zhang Q, Zeh HJ III, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clin Cancer Res (2013) 19(15):4046-57. doi:10.1158/1078-0432.CCR-13-0495